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a b s t r a c t
C-547, a potent slow-binding inhibitor of acetylcholinesterase (AChE) was intravenously administered to
rat (0.05mg/kg). Pharmacokinetic proﬁles were determined in blood and different organs: extensor
digitorum longus muscle, heart, liver, lungs and kidneys as a function of time. Pharmacokinetics (PK) was
studied using non-compartmental and compartmental analyses. A 3-compartment model describes PK in
blood. Most of injected C-547 binds to albumin in the bloodstream. The steady-state volume of distri-
bution (3800ml/kg) is 15 times larger than the distribution volume, indicating a good tissue distribution.
C-547 is slowly eliminated (kel¼ 0.17 h1; T1/2¼ 4 h) from the bloodstream.
Effect of C-547 on animal model ofmyasthenia gravis persists for more than 72 h, even though the drug
is not analytically detectable in the blood. A PK/PD model was built to account for such a pharmaco-
dynamical (PD) effect. Long-lasting effect results frommicro-PD mechanisms: the slow-binding nature of
inhibition, high afﬁnity for AChE and long residence time on target at neuromuscular junction (NMJ). In
addition, NMJ spatial constraints i.e. high concentration of AChE in a small volume, and slow diffusion
rate of free C-547 out of NMJ, make possible effective rebinding of ligand. Thus, compared to other
cholinesterase inhibitors used for palliative treatment of myasthenia gravis, C-547 is the most selective
drug, displays a slow pharmacokinetics, and has the longest duration of action. This makes C-547 a
promising drug leader for treatment ofmyasthenia gravis, and a template for development of other drugs
against neurological diseases and for neuroprotection.
© 2017 Elsevier Ltd. All rights reserved.
1. Introduction
Translational drug research implies a tight coupling between
molecular mechanisms, modeling, pharmacokinetics and pharma-
codynamics. This approach has been implemented for the discov-
ery of new drugs for the treatment of myasthenia gravis (MG). In
this respect, C-547, an alkylammonium derivative of 6-methyluracil
(Scheme 1) d potent inhibitor of acetylcholinesterase (AChE) d
was considered as a promising drug (Kharlamova et al., 2016;
Petrov et al., 2011). Unlike its non-charged analogue (C-35) that is
of potential interest for the treatment of Alzheimer disease
(Semenov et al., 2015), C-547 does not cross the blood-brain barrier
Abbreviations: ACh, acetylcholine; AChE, acetylcholinesterase; ATC, acetylth-
iocholine; BBB, blood brain barrier; BChE, butyrylcholinesterase; BK, binding ki-
netics; BSA, bovine serum albumin; C-547, 1,3-bis[5(diethyl-o-
nitrobenzylammonium)pentyl]-6-methyluracil dibromide; ChE, cholinesterase;
CMAP, compound muscle action potential; DTNB, dithiobisnitrobenzoic acid;
EAMG, experimental autoimmune myasthenia gravis; EDL, Extensor digitorum
longus muscle; iso-OMPA, tetraisopropyl pyrophosphoramide; MG, myasthenia
gravis; MRT, mean residence time; NMJ, neuromuscular junction; PK/PD, pharma-
cokinetics/pharmacodynamics; RBC, red blood cell.
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